

TMSDRDSI: Drug Design MSc

TMSDRDSING01: MSc Drug Design

WIBRG001, WIBRG002, WIBRG003, WIBRG004, 5 + 6

View Online



Alley, Stephen C, Nicole M Okeley, and Peter D Senter. 2010. 'Antibody–Drug Conjugates: Targeted Drug Delivery for Cancer'. *Current Opinion in Chemical Biology* 14 (4): 529–37. <https://doi.org/10.1016/j.cbpa.2010.06.170>.

Baurin, N., F. Aboul-Ela, X. Barril, B. Davis, M. Drysdale, B. Dymock, H. Finch, et al. 2004. 'Design and Characterization of Libraries of Molecular Fragments for Use in NMR Screening against Protein Targets'. *Journal of Chemical Information and Modeling* 44 (6): 2157–66. <https://doi.org/10.1021/ci049806z>.

Beck, Alain, Thierry Wurch, Christian Bailly, and Nathalie Corvaia. 2010. 'Strategies and Challenges for the next Generation of Therapeutic Antibodies'. *Nature Reviews Immunology* 10 (5): 345–52. <https://doi.org/10.1038/nri2747>.

Bissantz, Caterina, Bernd Kuhn, and Martin Stahl. 2010. 'A Medicinal Chemist's Guide to Molecular Interactions'. *Journal of Medicinal Chemistry* 53 (14): 5061–84. <https://doi.org/10.1021/jm100112j>.

Blake, J. F. 2005. 'Identification and Evaluation of Molecular Properties Related to Preclinical Optimization and Clinical Fate'. *Medicinal Chemistry* 1 (6): 649–55. <https://doi.org/10.2174/157340605774598081>.

Bradbury, Andrew R M, Sachdev Sidhu, Stefan Dübel, and John McCafferty. 2011. 'Beyond Natural Antibodies: The Power of in Vitro Display Technologies'. *Nature Biotechnology* 29 (3): 245–54. <https://doi.org/10.1038/nbt.1791>.

Brignier, Anne C., and Alan M. Gewirtz. 2010. 'Embryonic and Adult Stem Cell Therapy'. *Journal of Allergy and Clinical Immunology* 125 (2): S336–44. <https://doi.org/10.1016/j.jaci.2009.09.032>.

Castanotto, Daniela, and John J. Rossi. 2009. 'The Promises and Pitfalls of RNA-Interference-Based Therapeutics'. *Nature* 457 (7228): 426–33. <https://doi.org/10.1038/nature07758>.

Chandra, Nagasuma. 2009. 'Computational Systems Approach for Drug Target Discovery'. *Expert Opinion on Drug Discovery* 4 (12): 1221–36. <https://doi.org/10.1517/17460440903380422>.

Colquhoun, David. 1998. 'Binding, Gating, Affinity and Efficacy: The Interpretation of Structure-Activity Relationships for Agonists and of the Effects of Mutating Receptors'. *British Journal of Pharmacology* 125 (5): 923–47. <https://doi.org/10.1038/sj.bjp.0702164>.

- Congreve, Miles, Gianni Chessari, Dominic Tisi, and Andrew J. Woodhead. 2008. 'Recent Developments in Fragment-Based Drug Discovery'. *Journal of Medicinal Chemistry* 51 (13): 3661–80. <https://doi.org/10.1021/jm8000373>.
- Copeland, Robert Allen. 2005. *Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists*. Vol. *Methods of biochemical analysis*. Hoboken, N.J.: J. Wiley. <https://onlinelibrary.wiley.com/doi/book/10.1002/9781118540398>.
- Cornish-Bowden, Athel. 2004. *Fundamentals of Enzyme Kinetics*. 3rd ed. London: Portland.
- DiMasi, Joseph A, Ronald W Hansen, and Henry G Grabowski. 2003. 'The Price of Innovation: New Estimates of Drug Development Costs'. *Journal of Health Economics* 22 (2): 151–85. [https://doi.org/10.1016/S0167-6296\(02\)00126-1](https://doi.org/10.1016/S0167-6296(02)00126-1).
- Ducry, Laurent, and Bernhard Stump. 2010. 'Antibody–drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies'. *Bioconjugate Chemistry* 21 (1): 5–13. <https://doi.org/10.1021/bc9002019>.
- Dunlop, John. 2008. 'High-Throughput Electrophysiology: An Emerging Paradigm for Ion-Channel Screening and Physiology'. *Nature Reviews Drug Discovery* 7 (4): 358–68. <https://doi.org/10.1038/nrd2552>.
- Engel, Thomas and Gasteiger, J. 2003. *Chemoinformatics: A Textbook*.
- Fitt, R., and E. Nodder. 2010. 'Setting the Threshold for Industrial Application: The UK Diverges from Europe'. *Journal of Intellectual Property Law & Practice* 5 (8): 560–65. <https://doi.org/10.1093/jiplp/jpq061>.
- Gasteiger, J. 2003. *Handbook of Chemoinformatics: From Data to Knowledge*. <https://onlinelibrary.wiley.com/doi/book/10.1002/9783527618279>.
- Gibb, Alasdair J., Foreman, John C., and Johansen, Torben. 2011. *Textbook of Receptor Pharmacology*. 3rd ed. Boca Raton, FL: CRC Press.
- Grimm, Dirk. 2009. 'Small Silencing RNAs: State-of-the-Art'. *Advanced Drug Delivery Reviews* 61 (9): 672–703. <https://doi.org/10.1016/j.addr.2009.05.002>.
- Gu, Jenny and Bourne, Philip E. 2008. *Structural Bioinformatics*. 2nd ed. Vol. *Methods of biochemical analysis*. Hoboken, N.J.: Wiley.
- Holliger, Philipp, and Peter J Hudson. 2005. 'Engineered Antibody Fragments and the Rise of Single Domains'. *Nature Biotechnology* 23 (9): 1126–36. <https://doi.org/10.1038/nbt1142>.
- Hopkins, Andrew L., and Colin R. Groom. 2002. 'Opinion: The Druggable Genome'. *Nature Reviews Drug Discovery* 1 (9): 727–30. <https://doi.org/10.1038/nrd892>.
- Hopkins, Andrew L., Colin R. Groom, and Alexander Alex. 2004. 'Ligand Efficiency: A Useful Metric for Lead Selection'. *Drug Discovery Today* 9 (10): 430–31. [https://doi.org/10.1016/S1359-6446\(04\)03069-7](https://doi.org/10.1016/S1359-6446(04)03069-7).

'Human Embryonic Stem Cells: Derivation, Culture, and Differentiation: A Review'. n.d.

Ikura, Mitsuhiro, and Masayori Inouye. 1998. 'NMR Structure of the Histidine Kinase Domain of the : E. Coli: Osmosensor EnvZ : Article : Nature'. *Nature* 396 (6706): 88–92. <https://doi.org/10.1038/23968>.

Jarnagin, Kurt. 2001. Receptor Binding in Drug Discovery. *Encyclopedia of Life Sciences*. Chichester: John Wiley & Sons, Ltd. <https://doi.org/10.1038/npg.els.0000056>.

———. n.d. 'Receptor Binding in Drug Discovery'. In eLS.

Jinek, Martin, and Jennifer A. Doudna. 2009. 'A Three-Dimensional View of the Molecular Machinery of RNA Interference'. *Nature* 457 (7228): 405–12. <https://doi.org/10.1038/nature07755>.

Kalluri, Raghu, and Keizo Kanasaki. 2008. 'RNA Interference: Generic Block on Angiogenesis'. *Nature* 452 (7187): 543–45. <https://doi.org/10.1038/452543a>.

Kenakin, Terry P. 2009. 'Cellular Assays as Portals to Seven-Transmembrane Receptor-Based Drug Discovery'. *Nature Reviews Drug Discovery* 8 (8): 617–26. <https://doi.org/10.1038/nrd2838>.

Khawaja, Xavier, John Dunlop, and Dianne Kowal. 2008. 'Scintillation Proximity Assay in Lead Discovery'. *Expert Opinion on Drug Discovery* 3 (11): 1267–80. <https://doi.org/10.1517/17460441.3.11.1267>.

Kola, Ismail, and John Landis. 2004. 'Opinion: Can the Pharmaceutical Industry Reduce Attrition Rates?' *Nature Reviews Drug Discovery* 3 (8): 711–16. <https://doi.org/10.1038/nrd1470>.

Krohn, Kenneth A., and Jeanne M. Link. 2003. 'Interpreting Enzyme and Receptor Kinetics: Keeping It Simple, but Not Too Simple'. *Nuclear Medicine and Biology* 30 (8): 819–26. [https://doi.org/10.1016/S0969-8051\(03\)00132-X](https://doi.org/10.1016/S0969-8051(03)00132-X).

Leach, Andrew R. and Gillet, Valerie J. 2003. *An Introduction to Chemoinformatics*.

Lipinski, Christopher A., Franco Lombardo, Beryl W. Dominy, and Paul J. Feeney. 1997. 'Experimental and Computational Approaches to Estimate Solubility and Permeability in Drug Discovery and Development Settings'. *Advanced Drug Delivery Reviews* 23 (1–3): 3–25. [https://doi.org/10.1016/S0169-409X\(96\)00423-1](https://doi.org/10.1016/S0169-409X(96)00423-1).

Lledo, Pierre-Marie, Florian T. Merkle, and Arturo Alvarez-Buylla. 2008. 'Origin and Function of Olfactory Bulb Interneuron Diversity'. *Trends in Neurosciences* 31 (8): 392–400. <https://doi.org/10.1016/j.tins.2008.05.006>.

Macarron, Ricardo, Martyn N. Banks, Dejan Bojanic, David J. Burns, Dragan A. Cirovic, Tina Garyantes, Darren V. S. Green, et al. 2011. 'Impact of High-Throughput Screening in Biomedical Research'. *Nature Reviews Drug Discovery* 10 (3): 188–95. <https://doi.org/10.1038/nrd3368>.

Matter, Hans. 1997. 'Selecting Optimally Diverse Compounds from Structure Databases: A Validation Study of Two-Dimensional and Three-Dimensional Molecular Descriptors'.

Journal of Medicinal Chemistry 40 (8): 1219–29. <https://doi.org/10.1021/jm960352+>.

Murray, Christopher W. 2010. 'Fragment-Based Drug Discovery Applied to Hsp90. Discovery of Two Lead Series with High Ligand Efficiency'. Journal of Medicinal Chemistry 53 (16): 5942–55. <https://doi.org/10.1021/jm100059d>.

Murray, Christopher W., and David C. Rees. 2009. 'The Rise of Fragment-Based Drug Discovery'. Nature Chemistry 1 (3): 187–92. <https://doi.org/10.1038/nchem.217>.

Nagorsen, Dirk, and Patrick A. Baeuerle. 2011. 'Immunomodulatory Therapy of Cancer with T Cell-Engaging BiTE Antibody Blinatumomab'. Experimental Cell Research 317 (9): 1255–60. <https://doi.org/10.1016/j.yexcr.2011.03.010>.

Nelson, David L., Cox, Michael M., and Lehninger, Albert L. 2008. Lehninger Principles of Biochemistry. 5th ed. Basingstoke: W.H. Freeman.

Orengo, Christine Ann, Thornton, Janet M., and Jones, David Tudor. 2003. Bioinformatics: Genes, Proteins and Computers. Oxford: BIOS.
<http://www.vlebooks.com/vleweb/product/openreader?id=UCL&isbn=9780203427828>

Overington, John P., Bissan Al-Lazikani, and Andrew L. Hopkins. 2006. 'How Many Drug Targets Are There?' Nature Reviews Drug Discovery 5 (12): 993–96. <https://doi.org/10.1038/nrd2199>.

Patrick, Graham L. 2017. An Introduction to Medicinal Chemistry.

Petsko, Gregory A. and Ringe, Dagmar. 2004. Protein Structure and Function. Vol. Primers in biology. London: New Science.

Pillay, Vinochani, Hui K. Gan, and Andrew M. Scott. 2011. 'Antibodies in Oncology'. New Biotechnology 28 (5): 518–29. <https://doi.org/10.1016/j.nbt.2011.03.021>.

Rang, H. P. and Dale, M. Maureen. 2019. Pharmacology. 9th ed. Edinburgh: Churchill Livingstone. <https://elsevierelibrary.co.uk/product/9780702074462>.

Richard M. Durbin. 2010. 'A Map of Human Genome Variation from Population-Scale Sequencing'. Nature 467 (7319): 1061–73. <https://doi.org/10.1038/nature09534>.

Schrama, David, Ralph A. Reisfeld, and Jürgen C. Becker. 2006. 'Antibody Targeted Drugs as Cancer Therapeutics'. Nature Reviews Drug Discovery 5 (2): 147–59. <https://doi.org/10.1038/nrd1957>.

Selzer, P. M., Rohwer, A., and Marhöfer, R. J. 2008. Applied Bioinformatics: An Introduction. Berlin: Springer.

Shen, J, R Samul, R L Silva, H Akiyama, H Liu, Y Saishin, S F Hackett, et al. 2005. 'Suppression of Ocular Neovascularization with siRNA Targeting VEGF Receptor 1'. Gene Therapy 13 (3): 225–34. <https://doi.org/10.1038/sj.gt.3302641>.

Smith, Roger A. 2001. 'Discovery of Heterocyclic Ureas as a New Class of Raf Kinase Inhibitors: Identification of a Second Generation Lead by a Combinatorial Chemistry

Approach'. *Bioorganic & Medicinal Chemistry Letters* 11 (20): 2775–78.
[https://doi.org/10.1016/S0960-894X\(01\)00571-6](https://doi.org/10.1016/S0960-894X(01)00571-6).

Stadtfeld, M., and K. Hochedlinger. 2010. 'Induced Pluripotency: History, Mechanisms, and Applications'. *Genes & Development* 24 (20): 2239–63.
<https://doi.org/10.1101/gad.1963910>.

Swinney, David C., and Jason Anthony. 2011. 'How Were New Medicines Discovered?' *Nature Reviews Drug Discovery* 10 (7): 507–19. <https://doi.org/10.1038/nrd3480>.

Thomas, Gareth. 2003. *Fundamentals of Medicinal Chemistry*.

Vaishnaw, Akshay K, Jared Gollob, Christina Gamba-Vitalo, Renta Hutabarat, Dinah Sah, Rachel Meyers, Tony de Fougères, and John Maraganore. 2010. 'A Status Report on RNAi Therapeutics'. *Silence* 1 (1). <https://doi.org/10.1186/1758-907X-1-14>.

Veber, Daniel F., Stephen R. Johnson, Hung-Yuan Cheng, Brian R. Smith, Keith W. Ward, and Kenneth D. Kopple. 2002. 'Molecular Properties That Influence the Oral Bioavailability of Drug Candidates'. *Journal of Medicinal Chemistry* 45 (12): 2615–23.
<https://doi.org/10.1021/jm020017n>.

Watt, F. M., and R. R. Driskell. 2010. 'The Therapeutic Potential of Stem Cells'. *Philosophical Transactions of the Royal Society B: Biological Sciences* 365 (1537): 155–63.
<https://doi.org/10.1098/rstb.2009.0149>.

Webb, Sarah. 2011. 'Pharma Interest Surges in Antibody Drug Conjugates'. *Nature Biotechnology* 29 (4): 297–98. <https://doi.org/10.1038/nbt0411-297>.

Weiner, Louis M., Rishi Surana, and Shangzi Wang. 2010. 'Monoclonal Antibodies: Versatile Platforms for Cancer Immunotherapy'. *Nature Reviews Immunology* 10 (5): 317–27.
<https://doi.org/10.1038/nri2744>.

Welsch, Matthew E, Scott A Snyder, and Brent R Stockwell. 2010. 'Privileged Scaffolds for Library Design and Drug Discovery'. *Current Opinion in Chemical Biology* 14 (3): 347–61.
<https://doi.org/10.1016/j.cbpa.2010.02.018>.

Wilhelm, Scott. 2006. 'Discovery and Development of Sorafenib: A Multikinase Inhibitor for Treating Cancer'. *Nature Reviews Drug Discovery* 5 (10): 835–44.
<https://doi.org/10.1038/nrd2130>.

Willett, P., J.M. Barnard, and G.M. Downs. 1998. 'Chemical Similarity Searching'. *Journal of Chemical Information and Modeling* 38 (6): 983–96. <https://doi.org/10.1021/ci9800211>.

Woodhead, Andrew J. 2010. 'Discovery of (2,4-Dihydroxy-5-Isopropylphenyl)-[5-(4-Methylpiperazin-1-ylmethyl)-1,3-Dihydroisoindol-2-yl]Methanone (AT13387), a Novel Inhibitor of the Molecular Chaperone Hsp90 by Fragment Based Drug Design'. *Journal of Medicinal Chemistry* 53 (16): 5956–69.
<https://doi.org/10.1021/jm100060b>.

Xiong, Jin. 2006. *Essential Bioinformatics*. New York: Cambridge University Press.

Zvelebil, Marketa J. and Baum, Jeremy O. 2008. *Understanding Bioinformatics*. London:

Garland Science.

https://bibliu.com/app/#/view/books/9781136976964/pdf2htmlex/index.html#page_Cover.